- Home
- News & Events
- News
- Mapi Research Trust partners with Springer Nature.
Mapi Research Trust partners with Springer Nature to support Clinical Outcome Assessment resources.
April 6, 2023 – Lyon, France. Mapi Research Trust announces a new partnership with Springer Nature to support the distribution of Clinical Outcome Assessments (COAs) and manage users’ licensing requests.
Mapi Research Trust is the largest curator of COAs worldwide. Also known as instruments, questionnaires, measures, scales, tests, or measurement tools, COAs allow the measurement of the impact of diseases and treatments on patients’ quality of life*. Respecting the integrity of this scientific material and their measurement properties is thus paramount to ensure the validity of research work relying on COA data. This is why, to best protect COAs, copyright must be supplemented with the dissemination of comprehensive, up-to-date technical and scientific information.
As a renowned publisher of various journals in the field of patient-centered outcomes including BMC’s Health and Quality of Life Outcomes, and Springer’s Journal of Patient-Reported Outcomes and Quality of Life Research, Springer Nature has published numerous COAs and for many of them, controls their copyright.
Aligned with the goal to protect research integrity and facilitate rigorous scientific and research discovery, Mapi Research Trust will bring Springer Nature its 30 years of experience in collaborating with COA developers to manage all licensing requests and to support users of COAs with the appropriate information and essential material for proper use of COAs. These materials include the conditions of use, availability of translations and eCOAs, validation status and scoring guidance. In an ongoing collaboration with Springer Nature’s team, Mapi Research Trust experts will upload all, up-to-date key information into the ePROVIDETM platform, the reference for COA searches and licensing.
“It is a great honor for us at Mapi Research Trust to collaborate with the team of Springer Nature. We are very much looking forward to analyzing and centralizing all key materials related to their COAs to facilitate access and licensing requests for the entire scientific community.” said Caroline Anfray, Director of Author Collaborations at Mapi Research Trust.
Leslie Lansman, Global Permissions Manager at Springer Nature added “For more than 180 years, Springer Nature has been a trusted source for quality research. We remain committed to playing our role in supporting the research community with access to high quality, rigorously assessed research and resources supporting the advancement of knowledge and discovery. Partnering with Mapi Research Trust helps us facilitate this further across COA resources.”
About Springer Nature
For over 180 years Springer Nature has been advancing discovery by providing the best possible service to the whole research community. They help researchers uncover new ideas, make sure all the research they publish is significant, robust and stands up to objective scrutiny, that it reaches all relevant audiences in the best possible format, and can be discovered, accessed, used, re-used and shared. They support librarians and institutions with innovations in technology and data; and provide quality publishing support to societies.
As a research publisher, Springer Nature is home to trusted brands including Springer, Nature Portfolio, BMC, Palgrave Macmillan and Scientific American. For more information, please visit springernature.com and @SpringerNature.
About Mapi Research Trust
Mapi Research Trust is a non-profit organization that facilitates access to Clinical Outcome Assessments (COAs) for the entire scientific community. With more than 30 years of experience in the field of COAs and with the online platform ePROVIDE™, which includes databases on COAs (PROQOLID™), claims (PROLABELS™) and guidance (PROINSIGHT™), Mapi Research Trust is the pre-eminent source of information on COAs.
Exclusive distributor of over 700 COAs, Mapi Research Trust is the most trusted name in the distribution of COA instruments.
*More information on COAs can be found in the FDA’s article “Clinical Outcome Assessments in Medical Device Decision Making”, June 2022.